Johnson & Johnson May Be Forced To License Stents Patents To Complete Major Acquisition

Law360, New York (August 29, 2005, 12:00 AM EDT) -- The European Commission ruled this week Johnson & Johnson may need to license Guidant Corp.’s patents, which are held up in litigation, before acquisition of Guidant will be granted final approval.

The $25 billion dollar cash and stock deal would be the largest ever in the medical device industry and biggest in the 118-year history of Johnson & Johnson, maker of drugs, baby products, orthopedic and other health products.

Johnson & Johnson and Guidant are active worldwide in vascular medical devices, with their products used to...
To view the full article, register now.